 CAMBRIDGE, Mass., Sept. 15, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. Nasdaq: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. 